A good night’s sleep is invaluable. Big Pharma and smaller peers think so too, investing in treatments designed to improve the quantity and quality of sleep. Look at Eli Lilly of the US, paying up to $7.8bn for Centessa, one of whose narcolepsy drugs is readying for phase 3 efficacy trials. Sleep disorder biotech Avadel Pharmaceutical even spawned a bidding war, ultimately going to Ireland-headquartered Alkermes for up to $2.4bn.
一夜好眠价值无可估量。大型制药公司和规模较小的同行也这样认为，它们正投入资金研发旨在提升睡眠时长和质量的疗法。以美国礼来公司为例，该公司斥资最高78亿美元收购Centessa，后者有一款发作性睡病药物正准备开展III期有效性试验。睡眠障碍生物技术公司Avadel Pharmaceutical甚至引发了一场竞购战，最终由总部位于爱尔兰的Alkermes以最高24亿美元将其收入囊中。
您已阅读16%（624字），剩余84%（3308字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。